公开(公告)号：US12071425B2

公开(公告)日：2024-08-27

申请号：US17275606

申请日：2019-09-12

Applicant: Genentech, Inc.

Inventor： Marie-Gabrielle Braun ,  Cuong Q. Ly ,  Georgette Castanedo ,  Paul Gibbons ,  Wendy Lee ,  Joachim Rudolph ,  Nicole Alice Blaquiere ,  Jacob Bradley Schwarz ,  Ramsay Beveridge ,  Jean-Philippe Leclerc ,  Alexandre Lemire ,  Leo Fu

IPC: C07D401/14 ,  A61K45/06 ,  C07D401/04 ,  C07D413/14 ,  C07D471/04 ,  C07D471/08

CPC classification number: C07D401/14 ,  A61K45/06 ,  C07D401/04 ,  C07D413/14 ,  C07D471/04 ,  C07D471/08

Abstract: Described herein are phenoxy-pyridyl-pyrimidine compounds with inositol requiring enzyme 1 (IRE1) modulation activity or function having the Formula I structure or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such IRE1 modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.

公开(公告)号：US20240279327A1

公开(公告)日：2024-08-22

申请号：US18648653

申请日：2024-04-29

Applicant: Genentech, Inc.

Inventor： Germaine FUH ,  Chingwei V. LEE ,  Patrick KOENIG

IPC: C07K16/24 ,  A61K39/00 ,  A61K39/395 ,  A61K45/06 ,  C07K16/46

CPC classification number: C07K16/244 ,  A61K39/3955 ,  A61K45/06 ,  C07K16/247 ,  C07K16/468 ,  A61K2039/505 ,  C07K2317/14 ,  C07K2317/21 ,  C07K2317/31 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/92

Abstract: The invention provides dual specific antibodies and methods of making and using such antibodies. In general, the dual specific antibodies are generated by identification of a monospecific antibody having light chain variable region VL residues that are electrostatic or hydrophobic and altering the nucleic acid sequence encoding one or more solvent accessible residues in the VH of the antibody either alone or in combination with alteration of the nucleic acid sequence encoding the VL of the antibody. The altered VH and the VL are expressed and dual specific antibodies, or antigen-binding fragments thereof, are selected. Exemplary dual specific antibodies are also provided as well as methods of using the antibodies.

公开(公告)号：US20240277859A1

公开(公告)日：2024-08-22

申请号：US18682046

申请日：2022-08-22

Applicant: Genentech, Inc.

Inventor： Rachel Hendricks ,  Matthew Henry Hutchinson ,  Mark Frederick Fedesco ,  Bejamin Phu Tran

IPC: A61K47/68 ,  C07K1/107 ,  C07K1/18

CPC classification number: A61K47/68 ,  C07K1/1077 ,  C07K1/18

Abstract: The present invention relates to a method of developing purification processes for antibody drug conjugates using cation-exchange chromatography in flow-through mode leveraging the purification conditions of the antibody intermediate without a change to the critical quality attributes (CQA) of the ADC.

公开(公告)号：US20240261399A1

公开(公告)日：2024-08-08

申请号：US18364431

申请日：2023-08-02

Applicant: Genentech, Inc.

Inventor： Ariel LOPEZ-CHAVEZ ,  Daniel Antonius WATERKAMP

IPC: A61K39/395 ,  A61K9/00 ,  A61K31/365 ,  A61K33/243 ,  A61K39/00 ,  A61P35/00

CPC classification number: A61K39/3955 ,  A61K9/0019 ,  A61K31/365 ,  A61K33/243 ,  A61P35/00 ,  A61K2039/505

Abstract: The present disclosure provides methods for treating lung cancer (such as small cell lung cancer, e.g., extensive stage small cell lung cancer) in an individual. The methods comprise administering to the individual a PD-1 axis binding antagonist (such as an anti-PD-L1 antibody, e.g., atezolizumab), a platinum agent (e.g., cisplatin or carboplatin), and a topoisomerase II inhibitor (e.g., etoposide).

公开(公告)号：US20240254199A1

公开(公告)日：2024-08-01

申请号：US18489274

申请日：2023-10-18

Applicant: Genentech, Inc. ,  Hoffmann-La Roche Inc.

Inventor： Amy Shen ,  Inn Huam Yuk ,  Gavin Christian Barnard ,  Shahram Misaghi ,  Simon Auslaender ,  Niels Bauer ,  Benedikt Oswald

IPC: C07K16/00 ,  C12N5/00 ,  C12N9/22 ,  C12N15/11 ,  C12N15/90 ,  C12P21/00

CPC classification number: C07K16/00 ,  C12N5/00 ,  C12N9/22 ,  C12N15/11 ,  C12N15/907 ,  C12P21/00 ,  C12N2310/20 ,  C12N2800/80

Abstract: The present disclosure relates to mammalian cells (e.g., Chinese Hamster Ovary (CHO) cells) that are modified to reduce or eliminate the expression of certain mammalian cell endogenous products (e.g., host cell proteins and virus-like particles), and methods of using such cells in the production of a recombinant product of interest, e.g., a recombinant protein, a recombinant viral particle, or a recombinant viral vector. These modifications were specifically chosen to generate engineered mammalian host cells with desired traits in several key areas, including improved cell culture performance (e.g., higher viability and product titers), improved product quality (e.g., more consistent and favorable glycosylation; more stable drug product), and decreased burden on purification for removing problematic or undesired endogenous host cell products (e.g., hydrolytic host cell proteins and virus-like particles) during biomanufacturing.

公开(公告)号：US20240247034A1

公开(公告)日：2024-07-25

申请号：US18497741

申请日：2023-10-30

Applicant: Genentech, Inc.

Inventor： Rami HANNOUSH ,  Harini KALUARACHCHI ,  Aaron NILE ,  Cameron NOLAND ,  Yingnan ZHANG ,  Lijuan ZHOU ,  Xinxin GAO

IPC: C07K14/415 ,  A61K9/00 ,  A61K9/50 ,  A61K38/00 ,  A61K38/16 ,  A61K47/34 ,  C07K14/00 ,  C07K14/47 ,  C07K14/81

CPC classification number: C07K14/415 ,  A61K9/0051 ,  A61K9/5031 ,  A61K38/00 ,  A61K38/168 ,  A61K47/34 ,  C07K14/001 ,  C07K14/4702 ,  C07K14/811 ,  C07K2319/70

Abstract: Provided are non-naturally occurring cystine knot peptides (CKPs) that bind to VEGF-A. Additionally, provided are methods of using non-naturally occurring CKPs that bind to VEGF-A, including diagnostic and therapeutic compositions and methods. Non-naturally CKPs that bind low density lipoprotein receptor-related protein 6 (LRP6) are also provided.

公开(公告)号：US20240240156A1

公开(公告)日：2024-07-18

申请号：US18510297

申请日：2023-11-15

Applicant: Genentech, Inc.

Inventor： Amy Shen ,  Gavin Christian Barnard ,  Shuet Ming Yip

IPC: C12N5/071 ,  C07K16/00 ,  C12N9/22 ,  C12N15/11 ,  C12N15/85

CPC classification number: C12N5/0682 ,  C07K16/00 ,  C12N9/22 ,  C12N15/111 ,  C12N15/85 ,  C07K2317/622 ,  C12N2310/20 ,  C12N2840/002

Abstract: The presently disclosed subject matter relates to targeted integration (TI) host cells suitable for the expression of recombinant proteins where the TI host cells are also subjected to transposon-mediated genomic integration of one or more exogenous nucleic acids, as well as methods of producing and using said combined transposon-mediated genomic integration and TI host cells.

公开(公告)号：US20240228606A1

公开(公告)日：2024-07-11

申请号：US18612141

申请日：2024-03-21

Applicant: GENENTECH, INC.

Inventor： ChinYu LIN ,  Theodore A. OMACHI ,  Ryan P. OWEN ,  Karl YEN ,  Yanan ZHENG ,  Kendra DEBUSK

IPC: C07K16/24 ,  A61K9/00 ,  A61K9/19 ,  A61K31/573 ,  A61K39/00 ,  A61K39/395 ,  A61P17/00

CPC classification number: C07K16/244 ,  A61K9/0014 ,  A61K9/0024 ,  A61K9/19 ,  A61K31/573 ,  A61K39/3955 ,  A61P17/00 ,  A61K2039/505 ,  A61K2039/545 ,  C07K2317/24 ,  C07K2317/56 ,  C07K2317/76

Abstract: Uses of IL-13 antagonists for treating atopic dermatitis are provided. Also provided are methods of treating atopic dermatitis and methods of reducing the severity of atopic dermatitis by administering IL-13 antagonists.

公开(公告)号：US12030926B2

公开(公告)日：2024-07-09

申请号：US17171962

申请日：2021-02-09

Applicant: Genentech, Inc.

Inventor： Justin Scheer ,  Whitney Shatz ,  Domingos Ng

IPC: C07K16/00 ,  C07K16/46 ,  C12N15/79 ,  C12N15/90

CPC classification number: C07K16/00 ,  C07K16/468 ,  C07K2317/14 ,  C07K2317/31 ,  C07K2317/52 ,  C07K2317/526 ,  C07K2317/53 ,  C12N15/79 ,  C12N15/907

Abstract: Described herein are methods for the efficient production of antibodies and other multimeric protein complexes (collectively referred to herein as heteromultimeric proteins) capable of specifically binding to more than one target. The targets may be, for example, different epitopes located on a single molecule or located on different molecules.

公开(公告)号：US20240207398A1

公开(公告)日：2024-06-27

申请号：US18423520

申请日：2024-01-26

Applicant: Genentech, Inc. ,  Hoffmann-La Roche Inc.

Inventor： Qingyuan LIU ,  Anila TAHIRI ,  Zhao ZHANG ,  Edward Namserk CHA

IPC: A61K39/395 ,  A61K31/282 ,  A61K31/513 ,  A61K31/7068 ,  A61K38/17

CPC classification number: A61K39/3955 ,  A61K31/282 ,  A61K31/513 ,  A61K31/7068 ,  A61K38/1774

Abstract: The invention provides methods and compositions for use in treating cancer, e.g., gastric cancer (e.g., a gastric carcinoma (GC) or a gastroesophageal junction carcinoma (GEJC) (e.g., inoperable, locally advanced, metastatic, or advanced GC or GEJC)) or rectal cancer (e.g., locally advanced rectal cancer (LARC)) in a subject, for example, by administering to the subject a treatment regimen that includes an anti-TIGIT antagonist antibody (e.g., tiragolumab) in combination with a PD-1 axis binding antagonist (e.g., atezolizumab). The treatment regimen may be administered with chemotherapy or following a neoadjuvant chemotherapy regimen. Also provided are compositions (e.g., compositions comprising a PD-1 axis binding antagonist (e.g., atezolizumab) and/or an anti-TIGIT antagonist antibody (e.g., tiragolumab), including pharmaceutical compositions thereof, kits thereof, and articles of manufacture thereof) for use in treating cancer, e.g., gastric cancer (e.g., a GC or a GEJC (e.g., inoperable, locally advanced, metastatic, or advanced GC or GEJC)) or rectal cancer (e.g., LARC) in a subject.